.jpg)
.jpg) | |
Visioconférence - Développement d'un outil clinique pour mesurer la cognition chez les individus séropositifs Visioconférence - 1er Symposium sur la prise en charge clinique des hépatites virales 7e Symposium de Québec sur les aspects cliniques de l'infection par le VIH | |
 | |
 | |
CROI 2011 Journées québécoises VIH 2011 ACIIS-CANAC 2011 9th European Workshop on HIV & Hepatitis 15th International Workshop on HIV Observational Databases | |
 | |
1er Symposium sur la prise en charge clinique des hépatites virales
Le programme du symposium qui aura lieu le 29 avril 2011 est disponible. Vous pouvez vous inscrire dès maintenant.
Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men – Centers for Disease Control and Prevention
Lignes directrices intérimaires des CDC américains sur la prophylaxie pré-exposition chez les HARSAH.
Conference on Retroviruses and Opportunistic Infections (CROI)
CROI, l’une des plus importantes conférences en VIH, a débuté dimanche à Boston. HIVandHepatitis.com vous propose une couverture de l’événement.
Thérapie antirétrovirale
The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy
Clinical Infectious Diseases
Atazanavir Pharmacokinetics With and Without Tenofovir during Pregnancy
JAIDS
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
The Lancet Infectious Diseases
Résistance et mutations
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
AIDS Research and Therapy
Toxicité et interactions médicamenteuses
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients
Clinical Infectious Diseases
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation without Affecting HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo Controlled Clinical Trial
The Journal of Infectious Diseases
Co-infections
Incident Hepatitis C Virus Infection among US HIV-Infected Men Enrolled in Clinical Trials
Clinical Infectious Diseases
HIV Infection and the Liver: The Importance of HCV-HIV Coinfection and Drug-Induced Liver Injury
Clinics in Liver Disease
Infections opportunistes
Autres maladies associées
HIV Mono-infection Is Associated With FIB-4 – A Noninvasive Index of Liver Fibrosis – in Women
Clinical Infectious Diseases
Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus—Positive Women
The Journal of Infectious Diseases
Adhésion aux traitements
Prévention
Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men
MMWR (Lignes directrices intérimaires)
Autres
A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection
The Journal of Infectious Diseases
Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers
Journal of Virology
Hépatites
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C
Gastroenterology
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
Journal of Hepatology
Communiqué de presse
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV
Tibotec
Kaletra (lopinavir/ritonavir) Oral Solution label changes related to toxicity in preterm neonates
U. S. Food and Drug Administration
Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period
U. S. Food and Drug Administration
Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy
ViiV Healthcare
Programme National de Mentorat sur le VIH-SIDA (PNMVS)
300, rue Sainte-Catherine Est, 3e étage
Montréal, Québec, H2X 1L7
Téléphone : 514.282.9606
Télécopieur : 514.282.9607
Site web : www.pnmvs.org
Louis-Philippe Vézina, documentaliste
Courriel : doc@pnmvs.org
Pour toutes questions concernant le membership, les événements et les activités du PNMVS contacter:
Claude Pichette, adjoint à la coordination
Courriel : info@pnmvs.org